Correlates, change and 'state or trait' properties of insight in schizophrenia

Schizophrenia Research

Volumn 122, Issue 1-3, 2010, Pages 94-103

  Wiffen, Benjamin D R ^a   Rabinowitz, Jonathan ^b   Lex, Alice ^c   David, Anthony S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BAR ILAN UNIVERSITY   (Israel)

^c Janssen Cilag EMEA Belgium   (Belgium)

Author keywords

Antipsychotic; Functioning; Insight; Premorbid adjustment; Schizophrenia

Indexed keywords

RISPERIDONE;

ADULT; ARTICLE; AWARENESS; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG SAFETY; EDUCATION; EFFECT SIZE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL STATUS;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956228250     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.03.005     Document Type: Article

References (69)

1. Aleman A., Agrawal N., Morgan K.D., David A.S. Insight in psychosis and neuropsychological function: meta-analysis. Br. J. Psychiatry. 2006, 189(3):204-212.
2. Alloy L.B., Abramson L.Y. Judgment of contingency in depressed and nondepressed students: sadder but wiser?. J. Exp. Psychol. Gen. 1979, 108(4):441-485.
3. Insight and Psychosis: Awareness of Illness in Schizophrenia and Related Disorders 2004, Oxford University Press, New York, NY. 2nd ed. X.F. Amador, A.S. David (Eds.).
4. Amador X.F., Flaum M., Andreasen N.C., Strauss D.H., Yale S.A., Clark S.C., Gorman J.M. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch. Gen. Psychiatry. 1994, 51(10):826-836.
5. American Psychiatric Association, 1994. Diagnostic and statistical manual of mental disorders. 4th Ed. APA, Washington (DC).
6. American Psychiatric Association Global Assessment of Functioning (GAF) Scale. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition 2000, 34. American Psychiatric Association, Washington, DC.
7. Browne S., Garavan J., Gervin M., Roe M., Larkin C., O'Callaghan E. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J. Nerv. Ment. Dis. 1998, 186(2):74-78.
8. Buckley P.F., Wirshing D.A., Bhushan P., Pierre J.M., Resnick S.A., Wirshing W.C. Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs. 2007, 21(2):129-141.
9. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr. Bull. 1982, 8(3):470-484.
10. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr. Bull. 1982, 8(3):470-484.
11. Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd edn) 1976, Erlbaum, Hillsdale, NJ.
12. Cooke M.A., Peters E.R., Greenwood K.E., Fisher P.L., Kumari V., Kuipers E. Insight in psychosis: influence of cognitive ability and self-esteem. Br. J. Psychiatry. 2007, 191:234-237.
13. Cooke M.A., Fannon D., Kuipers E., Peters E., Williams S.C., Kumari V. Neurological basis of poor insight in psychosis: a voxel-based MRI study. Schizophr. Res. 2008, 103(1-3):40-51.
14. Cuesta M.J., Peralta V., Zarzuela A. Reappraising insight in psychosis. Multi-scale longitudinal study. Br J Psychiatry. 2000, 177:233-240.
15. Cuffel B.J., Alford J., Fischer E.P., Owen R.R. Awareness of illness in schizophrenia and outpatient treatment adherence. J. Nerv. Ment. Dis. 1996, 184(11):653-659.
16. David A.S. Insight and psychosis. Br. J. Psychiatry. 1990, 156(6):798-808.
17. David A.S. The clinical importance of insight: an overview. Insight and Psychosis: Awareness of Illness in Schizophrenia and Related Disorders 2004, Oxford University Press, Oxford. X.F. Amador, A.S. David (Eds.).
18. David A., Buchanan A., Reed A., Almeida O. The assessment of insight in psychosis. Br. J. Psychiatry. 1992, 161(5):599-602.
19. David A., van Os J., Jones P., Harvey I., Foerster A., Fahy T. Insight and psychotic illness. Cross-sectional and longitudinal associations. Br. J. Psychiatry 1995, 167(5):621-628.
20. Debowska G., Grazwa A., Kucharska-Pietura K. Insight in paranoid schizophrenia-its relationship to psychopathology and premorbid adjustment. Compr. Psychiatry. 1998, 39(5):255-260.
21. Dickerson F., Boronow J., Ringel N., Parente F. Lack of insight among outpatients with schizophrenia. Psychiatr. Serv. 1997, 48(2):195-199.
22. Doyle M., Flanagan S., Browne S., Clarke M., Lydon D., Larkin C., O'Callaghan E. Subjective and external assessments of quality of life in schizophrenia: relationship to insight. Acta Psychiatr. Scand. 1999, 99(6):466-472.
23. Drake R.J., Dunn G., Tarrier N., Bentall R.P., Haddock G., Lewis S.W. Insight as a predictor of the outcome of First-Episode Nonaffective Psychosis in a Prospective Cohort Study in England. J. Clin. Psychiatry. 2007, 68(1):81-86.
24. Eberhard J., Levander S., Lindstrom E. Remission in schizophrenia: analysis in a naturalistic setting. Compr Psychiatry. 2009, 50(3):200-208.
25. FDA. Good Clinical Practice in FDA-Regulated Clinical Trials 2005: Available from: http://www.fda.gov/oc/gcp/default.htm.
26. Gharabawi G.M., Lasser R.A., Bossie C.A., Zhu Y., Amador X. Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. Int. Clin. Psychopharmacol. 2006, 21(4):233-240.
27. Gharabawi G., Bossie C., Turkoz I., Kujawa M., Mahmoud R., Simpson G. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. J. Nerv. Ment. Dis. 2007, 195(12):976-982.
28. Goldberg R.W., Green-Paden L.D., Lehman A.F., Gold J.M. Correlates of insight in serious mental illness. J. Nerv. Ment. Dis. 2001, 189(3):137-145.
29. Gray R., Wykes T., Edmonds M., Leese M., Gournay K. Effect of a medication management training package for nurses on clinical outcomes for patients with schizophrenia: cluster randomised controlled trial. Br. J. Psychiatry. 2004, 185(2):157-162.
30. Hasson-Ohayon I., Kravetz S., Roe D., David A.S., Weiser M. Insight into psychosis and quality of life. Compr. Psychiatry. 2006, 47(4):265-269.
31. Karow A., Pajonk F.G., Reimer J., Hirdes F., Osterwald C., Naber D., Moritz S. The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(3):152-159.
32. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
33. Kay S.R., Opler L.A., Fiszbein A. The Structured Clinical Interview for the Positive and Negative Syndromes of Schizophrenia 1992, Multi-Health Systems, New York.
34. Kemp R., David A.S. Insight and compliance. Treatment Compliance and the Therapeutic Alliance 1997, 61-86. Harwood Academic Publishers, Amsterday. B. Blackwell (Ed.).
35. Kemp R., Hayward P., Applewhaite G., Everitt B., David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996, 312(7027):345-349.
36. Kemp R., Kirov G., Everitt B., Hayward P., David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br. J. Psychiatry. 1998, 172(5):413-419.
37. Keshavan M.S., Rabinowitz J., DeSmedt G., Harvey P.D., Schooler N. Correlates of insight in first episode psychosis. Schizophr. Res. 2004, 70(2-3):187-194.
38. Lewis A. The psychopathology of insight. British Journal of Medical Psychology 1934, 14:332-348.
39. Lincoln T.M., Lullmann E., Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. A Systematic Review. Schizophr. Bull. 2007, 33(6):1324-1342.
40. Lysaker P.H., Bell M.D., Bryson G.J., Kaplan E. Insight and interpersonal function in schizophrenia. J. Nerv. Ment. Dis. 1998, 186(7):432-436.
41. Macpherson R., Jerrom B., Hughes A. Relationship between insight, educational background and cognition in schizophrenia. Br. J. Psychiatry. 1996, 168(6):718-722.
42. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry. 1997, 58(12):538-546.
43. Markova I.S. Insight and Psychiatry 2005, Cambridge University Press, Cambridge.
44. McEvoy J.P., Freter S., Everett G., Geller J.L., Appelbaum P., Apperson L.J., Roth L. Insight and the clinical outcome of schizopheric patients. J. Nerv. Ment. Dis. 1989, 177(1):48-51.
45. McEvoy J.P., Johnson J., Perkins D., Lieberman J.A., Hamer R.M., Keefe R.S., Tohen M., Glick I.D., Sharma T. Insight in first-episode psychosis. Psychol. Med. 2006, 36(10):1385-1393.
46. Mintz A.R., Dobson K.S., Romney D.M. Insight in schizophrenia: a meta-analysis. Schizophr. Res. 2003, 61(1):75-88.
47. Mintz A.R., Addington J., Addington D. Insight in early psychosis: a 1-year follow-up. Schizophr. Res. 2004, 67(2-3):213-217.
48. Mohamed S., Rosenheck R., McEvoy J., Swartz M., Stroup S., Lieberman J.A. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr. Bull. 2009, 35(2):336-346.
49. Morgan K.D., David A.S. Neuropsychological studies of insight in patients with psychotic disorders. Insight and Psychosis: Awareness of Illnes in Schizophrenia and Related Disorders 2004, Oxford University Press, Oxford. X.F. Amador, A.S. David (Eds.).
50. Napryeyenko O., Burba B., Martinez G., Neznanov N.G., Fischel T., Baylé F.J., Corrivetti G., Smeraldi E. Risperidone long-acting injectable in recent-onset schizophrenia examined with clinician and patient self-report measures. J. Clin. Psychopharmacol. 2010, 30(2):1-3.
51. Owen G.S., David A.S., Richardson G., Szmukler G., Hayward P., Hotopf M. Mental capacity, diagnosis and insight in psychiatric in-patients: a cross-sectional study. Psychol. Med. 2009, 39(08):1389-1398.
52. Patel M.X., de Zoysa N., M.B., David A.S. A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral. J. Clin. Psychiatry. 2008, 69(10):1548.
53. Patel M., De Zoysa N., Bernadt M., David A. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J. Psychopharmacol. (Oxf.). 2009, 23(7):789-796.
54. Rabinowitz J., Levine S.Z., Brill N., Bromet E.J. The premorbid adjustment scale structured interview (PAS-SI): preliminary findings. Schizophr Res. 2007, 90(1-3):255-257.
55. Rathod S., Kingdon D., Smith P., Turkington D. Insight into schizophrenia: the effects of cognitive behavioural therapy on the components of insight and association with sociodemographics-data on a previously published randomised controlled trial. Schizophr. Res. 2005, 74(2-3):211-219.
56. Roseman A.S., Kasckow J., Fellows I., Osatuke K., Patterson T.L., Mohamed S., Zisook S. Insight, quality of life, and functional capacity in middle-aged and older adults with schizophrenia. Int. J. Geriatr. Psychiatry. 2008, 23(7):760-765.
57. Rosen K., Garety P. Predicting recovery from schizophrenia: a retrospective comparison of characteristics at onset of people with single and multiple episodes. Schizophr. Bull. 2005, 31(3):735-750.
58. Saeedi H., Addington J., Addington D. The association of insight with psychotic symptoms, depression, and cognition in early psychosis: a 3-year follow-up. Schizophr. Res. 2007, 89(1-3):123-128.
59. Sanz M., Constable G., Lopez-Ibor I., Kemp R., David A. A comparative study of insight scales and their relationship to psychopathological and clinical variables. Psychol. Med. 1998, 28(2):437-446.
60. Sapara A., Cooke M., Fannon D., Francis A., Buchanan R.W., Anilkumar A.P., Barkataki I., Aasen I., Kuipers E., Kumari V. Prefrontal cortex and insight in schizophrenia: a volumetric MRI study. Schizophr. Res. 2007, 89(1-3):22-34.
61. Saravanan, B., Jacob, K.S., Johnson, S., Prince, M., Bhugra, D., David, A.S., in press. A longitudinal study of outcome of first episode schizophrenia in India: the effect of insight and psychopathology. Br. J. Psychiatry.
62. Schwartz R.C. Insight and illness in chronic schizophrenia. Compr. Psychiatry. 1998, 39(5):249-254.
63. Shad M.U., Keshavan M.S., Tamminga C.A., Cullum C., David A. Neurobiological underpinnings of insight deficits in schizophrenia. Int. Rev. Psychiatry. 2007, 19(4):439-448.
64. Simon A.E., Berger G.E., Giacomini V., Ferrero F., Mohr S. Insight, symptoms and executive functions in schizophrenia. Cognit. Neuropsychiatry. 2006, 11(5):437-451.
65. Smith T.E., Hull J.W., Goodman M., Hedayat-Harris A., Willson D.F., Israel L.M., Munich R.L. The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J. Nerv. Ment. Dis. 1999, 187(2):102-108.
66. Ware J.E., Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998, 51(11):903-912.
67. White R., Bebbington P., Pearson J., Johnson S., Ellis D. The social context of insight in schizophrenia. Soc. Psychiatry Psychiatr. Epidemiol. 2000, 35(11):500-507.
68. Wiffen, B. D. R., Rabinowitz, J., Fleischhacker, W. W., David, A. S., in press. Insight: demographic differences and associations with outcome over 1year in a large cohort of patients with schizophrenia and schizoaffective disorder. Clinical Schizophrenia & Related Psychoses.
69. Williams C.C., Collins A. Factors associated with insight among outpatients with serious mental illness. Psychiatr. Serv. 2002, 53(1):96-98.